CA2268546A1 - Composition, for the treatment of asthma, containing loratadine and a decongestant - Google Patents
Composition, for the treatment of asthma, containing loratadine and a decongestant Download PDFInfo
- Publication number
- CA2268546A1 CA2268546A1 CA002268546A CA2268546A CA2268546A1 CA 2268546 A1 CA2268546 A1 CA 2268546A1 CA 002268546 A CA002268546 A CA 002268546A CA 2268546 A CA2268546 A CA 2268546A CA 2268546 A1 CA2268546 A1 CA 2268546A1
- Authority
- CA
- Canada
- Prior art keywords
- decongestant
- loratadine
- asthma
- pseudoephedrine
- milligrams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention encompasses a method for improving pulmonary function of a patient suffering from asthma, comprising administering to the patient customary rhinitis treatment-effective amounts of loratadine and a decongestant such as pseudoephedrine.
Description
COMPOSITION, FOR THE TREATMENT OF ASTHMA, CONTAINING LORATADINE AND A
DECONGESTANT
INTRODUCTION TO THE INVENTION
The invention relates to methods for relieving symptoms of allergic diseases, and more particularly to relieving bronchial asthma symptoms.
Asthma is considered to be a very serious chronic allergic disorder, and is typically characterized by airway hyperresponsiveness, recurrent airflow obstruction and symptoms of cough, wheezing and breathlessness. It is one of the most common chronic diseases of childhood, perhaps affecting as many as ten percent of children. Asthma is economically very significant, as it causes considerable time loss from jobs and school, is one of the most common reasons for visits to the physician and is responsible for many admissions to emergency treatment facilities and hospitals. Asthma is also responsible for significant mortality, particularly when not properly treated.
It is generally accepted that asthma is characterized by chronic airway inflammation, varying degrees of airway obstruction which is usually reversible, and increases in airway responsiveness to a variety of stimuli. Muscle spasm, airway edema, abnormal mucous production and an inflammatory cell . 35 filtrate can often be observed during an acute exacerbation, frequently referred to by sufferers as "an asthma attack."
Airway edema and bronchospasm usually can be successfully treated with bronchodilators, such as epinephrine and the (3z-agonists albuterol (also called "salbutamol"), metaproterenol, pirbuterol, terbutaline and salmeterol. Airway narrowing can usually be blocked by administering systemic corticosteroids, such as prednisone, or inhaled anti-inflammatory drugs such as beclomethasone dipropionate, flunisolide, triamcinolone acetonide, cromolyn sodium and nedocromil sodium. The ~i2-agonists are used as daily maintenance medications and as "rescue" medications, when they are administered as needed when exacerbated symptoms are experienced. Systemic corticosteroids are given therapeutically, usually in large doses, for treatment of status asthmaticus, while the corticosteroids are prophylactic and are typically administered for the more severe cases in regular, spaced doses regardless of current symptoms. Action of these treatments results in relief from cough, wheezing and the feeling of breathlessness, plus a reduction in airway narrowing which can easily be quantified by measuring improvements in the patient's forced expiratory volume (FEV) or peak expiratory flow (PEF) rate values; the determination and significance of these parameters are discussed at pages 584-599 of R. Berkow, Ed., The Merck Manual of Diagnosis and Therapy, Fifteenth Edition, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey, 1987, particularly at pages 588-9. Some patients further require additional oral, injected and/or inhaled medications to control their disease, the ultimate objective of treatment being to eliminate acute exacerbations.
Studies have shown that about 11 percent of patients with nasal allergy symptoms also suffer from asthma, and that as many as 80 percent of bronchial asthma sufferers may also have allergic rhinitis.
Histamine has been implicated as a pathogenic mediator in both upper and lower airway diseases, and studies have been conducted to determine the effect of histamine H1 receptor antagonist "antihistamines" on asthma symptoms. With the older drugs, frequently identified as "sedating" antihistamines, their anticholinergic effects were generally found to be detrimental to asthma patients, and it is thus the conventional thought that antihistaminic drugs are contraindicated for asthmatics. Typical advice is that given by J. E. Donnelly et al., "Inadequate Parental Understanding of Asthma Medications," Annals of Alleray, Vol. 62, pages 337-341 (1989) where it is stated at pages 338-9:
It can be observed that substantial percentages of children had received antibiotics, antihistamines and decongestants for their asthma... These three groups of drugs have no place in the treatment of childhood asthma.
However, the advent of antihistamines having a reduced sedation effect (such as cetirizine) and nonsedating antihistamines {such as terfenadine and loratadine) have renewed interest in treating asthma with antihistamines. It is stated by P. V. Williams et al. in the chapter entitled "Asthma in Children" of R.
E. Rakel, ed., Conn's Current Therapy 1995, W. B.
Saunders Co., Philadelphia, Pennsylvania, 1995, pages 682-691, at page 686 that:
Antihistamines are weak bronchodilators, and newer agents, many of which are not available in the United States, have some anti-inflammatory properties. They are not as effective as other medications available for the treatment of asthma, and thus do not have a role in routine asthma management.. They are mentioned here, however, to counteract the statements found in many package - inserts that antihistamines should not be used in patients with asthma. Their use in patients with upper airway allergies is not contraindicated if the patient has asthma and they may have a beneficial effect on the asthma as well.
Studies performed with the usual allergic rhinitis treatment doses of the reduced sedating antihistamine drug cetirizine include those reported in the following articles: G. Bruttman et al., "Protective Effect of Cetirizine in Patients Suffering from Pollen Asthma,"
Annals of Alleray, Vol. 64, pages 224-228 (1990); J. H.
Dijkman et al., "Prophylactic Treatment of Grass Pollen-Induced Asthma with Cetirizine," Clinical and Experimental Allergy, Vol. 20, pages 483-490 (1990); J.
A. Grant et al., "Cetirizine in Patients with Seasonal Rhinitis and Concomitant Asthma: Prospective, Randomized, Placebo-Controlled Trial," The Journal of Allergy and Clinical Immunology, Vol. 95, pages 923-932 (1995); and D. W. Aaronson, "Evaluation of Cetirizine in Patients with Allergic Rhinitis and Perennial Asthma," Annals of Alleray, Asthma and Immunoloay, Vol.
76, pages 440-446 (1996). It was generally found that cetirizine caused some improvement in asthma symptoms such as chest tightness, wheezing, shortness of breath and cough, together with relief of the rhinitis symptoms. However, no significant improvement in pulmonary function has been shown, as measured by FEV
values and other parameters.
Terfenadine has also been studied, as reported by:
A. Taytard et al., "Treatment of Bronchial Asthma with Terfenadine; a Randomised Controlled Trial," British Journal of Clinical Pharmacoloay, Vol. 24, pages 743-746 (1987); P. Rafferty et al., "Terfenadine, a Potent Histamine H1-Receptor Antagonist in the Treatment of Grass Pollen Sensitive Asthma," British Journal of Clinical Pharmacoloav, Vol. 30, pages 229-235 (1990);
and R. Wood-Baker et al., "A Double-Blind, Placebo Controlled Study of the Effect of the Specific Histamine H1-Receptor Antagonist, Terfenadine, in Chronic Severe Asthma," British Journal of Clinical Pharmacoloay, Vol. 39, pages 671-675 (1995). Twice the usual dose for allergic rhinitis, or 120 milligrams of terfenadine twice daily, had at best a slight positive effect on pulmonary function. However, the dosing regimen used by Rafferty et al., 180 milligrams three times per day, resulted in increased PEF values by 5.5 percent in the morning and 6.2 percent in the evening.
Due to the well-known cardiotoxicity potential of this drug, routine administration of abnormally large doses may not be wise.
A. Dirksen et al., "Effect of a Non-Sedative Antihistaminic (Loratadine) in Moderate Asthma,"
Alleray, Vol. 44, pages 566-571 (1989) reported the results of a study which administered a normal allergic rhinitis treatment dose of loratadine (10 milligrams, once daily) to asthmatics. Patients exhibited a lessening of asthma symptoms with the treatment, but showed only small improvements in pulmonary function which were described as not statistically significant.
Decongestant drugs are often used to treat allergic rhinitis. The most significant of these are sympathomimetic amines having a-adrenergic stimulating activity. Among the more widely used orally delivered agents are phenylpropanolamine, ephedrine and pseudoephedrine. Decongestants have long been used in combination with antihistamines for treating allergic and other forms of rhinitis, and some of the publications discussed above relating to cetirizine and terfenadine studies indicate that patients in the antihistamine clinical studies were allowed to use pseudoephedrine for additional relief of symptoms.
However, there is no unexpected benefit attributed to this use.
DECONGESTANT
INTRODUCTION TO THE INVENTION
The invention relates to methods for relieving symptoms of allergic diseases, and more particularly to relieving bronchial asthma symptoms.
Asthma is considered to be a very serious chronic allergic disorder, and is typically characterized by airway hyperresponsiveness, recurrent airflow obstruction and symptoms of cough, wheezing and breathlessness. It is one of the most common chronic diseases of childhood, perhaps affecting as many as ten percent of children. Asthma is economically very significant, as it causes considerable time loss from jobs and school, is one of the most common reasons for visits to the physician and is responsible for many admissions to emergency treatment facilities and hospitals. Asthma is also responsible for significant mortality, particularly when not properly treated.
It is generally accepted that asthma is characterized by chronic airway inflammation, varying degrees of airway obstruction which is usually reversible, and increases in airway responsiveness to a variety of stimuli. Muscle spasm, airway edema, abnormal mucous production and an inflammatory cell . 35 filtrate can often be observed during an acute exacerbation, frequently referred to by sufferers as "an asthma attack."
Airway edema and bronchospasm usually can be successfully treated with bronchodilators, such as epinephrine and the (3z-agonists albuterol (also called "salbutamol"), metaproterenol, pirbuterol, terbutaline and salmeterol. Airway narrowing can usually be blocked by administering systemic corticosteroids, such as prednisone, or inhaled anti-inflammatory drugs such as beclomethasone dipropionate, flunisolide, triamcinolone acetonide, cromolyn sodium and nedocromil sodium. The ~i2-agonists are used as daily maintenance medications and as "rescue" medications, when they are administered as needed when exacerbated symptoms are experienced. Systemic corticosteroids are given therapeutically, usually in large doses, for treatment of status asthmaticus, while the corticosteroids are prophylactic and are typically administered for the more severe cases in regular, spaced doses regardless of current symptoms. Action of these treatments results in relief from cough, wheezing and the feeling of breathlessness, plus a reduction in airway narrowing which can easily be quantified by measuring improvements in the patient's forced expiratory volume (FEV) or peak expiratory flow (PEF) rate values; the determination and significance of these parameters are discussed at pages 584-599 of R. Berkow, Ed., The Merck Manual of Diagnosis and Therapy, Fifteenth Edition, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey, 1987, particularly at pages 588-9. Some patients further require additional oral, injected and/or inhaled medications to control their disease, the ultimate objective of treatment being to eliminate acute exacerbations.
Studies have shown that about 11 percent of patients with nasal allergy symptoms also suffer from asthma, and that as many as 80 percent of bronchial asthma sufferers may also have allergic rhinitis.
Histamine has been implicated as a pathogenic mediator in both upper and lower airway diseases, and studies have been conducted to determine the effect of histamine H1 receptor antagonist "antihistamines" on asthma symptoms. With the older drugs, frequently identified as "sedating" antihistamines, their anticholinergic effects were generally found to be detrimental to asthma patients, and it is thus the conventional thought that antihistaminic drugs are contraindicated for asthmatics. Typical advice is that given by J. E. Donnelly et al., "Inadequate Parental Understanding of Asthma Medications," Annals of Alleray, Vol. 62, pages 337-341 (1989) where it is stated at pages 338-9:
It can be observed that substantial percentages of children had received antibiotics, antihistamines and decongestants for their asthma... These three groups of drugs have no place in the treatment of childhood asthma.
However, the advent of antihistamines having a reduced sedation effect (such as cetirizine) and nonsedating antihistamines {such as terfenadine and loratadine) have renewed interest in treating asthma with antihistamines. It is stated by P. V. Williams et al. in the chapter entitled "Asthma in Children" of R.
E. Rakel, ed., Conn's Current Therapy 1995, W. B.
Saunders Co., Philadelphia, Pennsylvania, 1995, pages 682-691, at page 686 that:
Antihistamines are weak bronchodilators, and newer agents, many of which are not available in the United States, have some anti-inflammatory properties. They are not as effective as other medications available for the treatment of asthma, and thus do not have a role in routine asthma management.. They are mentioned here, however, to counteract the statements found in many package - inserts that antihistamines should not be used in patients with asthma. Their use in patients with upper airway allergies is not contraindicated if the patient has asthma and they may have a beneficial effect on the asthma as well.
Studies performed with the usual allergic rhinitis treatment doses of the reduced sedating antihistamine drug cetirizine include those reported in the following articles: G. Bruttman et al., "Protective Effect of Cetirizine in Patients Suffering from Pollen Asthma,"
Annals of Alleray, Vol. 64, pages 224-228 (1990); J. H.
Dijkman et al., "Prophylactic Treatment of Grass Pollen-Induced Asthma with Cetirizine," Clinical and Experimental Allergy, Vol. 20, pages 483-490 (1990); J.
A. Grant et al., "Cetirizine in Patients with Seasonal Rhinitis and Concomitant Asthma: Prospective, Randomized, Placebo-Controlled Trial," The Journal of Allergy and Clinical Immunology, Vol. 95, pages 923-932 (1995); and D. W. Aaronson, "Evaluation of Cetirizine in Patients with Allergic Rhinitis and Perennial Asthma," Annals of Alleray, Asthma and Immunoloay, Vol.
76, pages 440-446 (1996). It was generally found that cetirizine caused some improvement in asthma symptoms such as chest tightness, wheezing, shortness of breath and cough, together with relief of the rhinitis symptoms. However, no significant improvement in pulmonary function has been shown, as measured by FEV
values and other parameters.
Terfenadine has also been studied, as reported by:
A. Taytard et al., "Treatment of Bronchial Asthma with Terfenadine; a Randomised Controlled Trial," British Journal of Clinical Pharmacoloay, Vol. 24, pages 743-746 (1987); P. Rafferty et al., "Terfenadine, a Potent Histamine H1-Receptor Antagonist in the Treatment of Grass Pollen Sensitive Asthma," British Journal of Clinical Pharmacoloav, Vol. 30, pages 229-235 (1990);
and R. Wood-Baker et al., "A Double-Blind, Placebo Controlled Study of the Effect of the Specific Histamine H1-Receptor Antagonist, Terfenadine, in Chronic Severe Asthma," British Journal of Clinical Pharmacoloay, Vol. 39, pages 671-675 (1995). Twice the usual dose for allergic rhinitis, or 120 milligrams of terfenadine twice daily, had at best a slight positive effect on pulmonary function. However, the dosing regimen used by Rafferty et al., 180 milligrams three times per day, resulted in increased PEF values by 5.5 percent in the morning and 6.2 percent in the evening.
Due to the well-known cardiotoxicity potential of this drug, routine administration of abnormally large doses may not be wise.
A. Dirksen et al., "Effect of a Non-Sedative Antihistaminic (Loratadine) in Moderate Asthma,"
Alleray, Vol. 44, pages 566-571 (1989) reported the results of a study which administered a normal allergic rhinitis treatment dose of loratadine (10 milligrams, once daily) to asthmatics. Patients exhibited a lessening of asthma symptoms with the treatment, but showed only small improvements in pulmonary function which were described as not statistically significant.
Decongestant drugs are often used to treat allergic rhinitis. The most significant of these are sympathomimetic amines having a-adrenergic stimulating activity. Among the more widely used orally delivered agents are phenylpropanolamine, ephedrine and pseudoephedrine. Decongestants have long been used in combination with antihistamines for treating allergic and other forms of rhinitis, and some of the publications discussed above relating to cetirizine and terfenadine studies indicate that patients in the antihistamine clinical studies were allowed to use pseudoephedrine for additional relief of symptoms.
However, there is no unexpected benefit attributed to this use.
SUMMARY OF THE INVENTION
The invention encompasses a method for improving pulmonary function of a patient suffering from asthma, comprising administering to the patient the customary rhinitis treatment-effective amounts of loratadine and a decongestant.
A preferred decongestant is pseudoephedrine, and a presently preferred daily treatment for obtaining the desired results of the invention includes 10 milligrams of loratadine and one of: 240 milligrams of pseudoephedrine, administered in a suitable extended release formulation for 24-hour effectiveness; or two daily doses of 5 milligrams of loratadine and 120 milligrams of pseudoephedrine, administered in an extended release formulation for 12-hour effectiveness;
or in up to four divided doses of immediate release formulations during 24 hours, totalling 10 milligrams of loratadine and 240 milligrams of pseudoephedrine.
Particularly with the immediate release formulations, the individual drugs can be administered separately or in a combination dosage form.
BRIEF DESCRIPTIONS OF THE DRAWINGS
Fig. 1 is a graphical representation of morning PEF data obtained in the clinical test of the example.
Fig. 2 is a graphical representation of evening PEF data obtained in the clinical test of the example.
Fig. 3 is a graphical representation of FEV data obtained in the clinical test of the example.
_7-DETAILED DESCRIPTION OF THE INVENTION
A reference herein to "customary rhinitis-effective treatment amounts" of a drug is intended to indicate those doses which are approved by any relevant regulatory agencies, such as the United States Food and Drug Administration, for use of the drug to treat symptoms of allergic rhinitis. References herein to "improving pulmonary function" are meant to include a facilitation of gas exchange processes in the lungs, particularly as shown clinically by improvements in measured FEV and/or PEF values for a patient; such improvements will usually be accompanied by a reduction in the patient's perception of shortness of breath.
Loratadine, chemically ethyl-4-(8-chloro-5,6-dihydro-11H-benzo [5, 6] cyclohepta [1, 2-b) pyridin-11-ylidene)-1-piperidinecarboxylate with an empirical formula CZZHzsC1N2O2 and a molecular weight of 382.89, is a very widely used nonsedating antihistamine drug with a superb safety profile. The active drug and its preparation are described in United States Patent 4,282,233 to Vilani. The drug may also conveniently be prepared according to the process described in United States Patent 4,731,447 to Schumacher et al. For purposes of the present invention, loratadine may be administered in any of several dosage forms, including, without limitation, tablets, capsules, syrups or by injection; as with most drugs, oral administration in the form of a tablet or capsule will be preferred for patient convenience.
An effective antihistaminic dose of loratadine ranges from about 5 to about 40 milligrams daily. Due to the systemic half-lives of loratadine and its active metabolites, the daily dose may be given once each 24 hours or divided into 2, 3, or 4 preferably equal portions for administration to match the frequency of decongestant drug dosing. A typical daily dose of _g_ loratadine for relief of the symptoms of allergic rhinitis is 10 milligrams. Schering Corporation of Kenilworth, New Jersey markets a 10 milligram loratadine tablet under the brand CLARITIN~.
Useful decongestant drugs include topical decongestants and systemic decongestants. Topical decongestants are typically administered in the form of drops or aerosols such as nasal sprays, and contain such drugs as oxymetazoline, phenylephrine, naphazoline, xylometazoline, ephedrine, epinephrine, methylhexaneamine, tetrahydrozoline and xylometazoline.
Topical decongestants are not preferred for long-term therapy, due to the eventual appearance of rhinitis medicamentosa which can usually be treated only by discontinuing administration of the drug.
Suitable systemic decongestant drug compounds for the practice of the invention include the sympathomimetic amines phenylpropanolamine, ephedrine, pseudoephedrine and phenylephrine, a reference herein to the drug specifically including pharmaceutically acceptable salts thereof, where necessary. The most widely used of these is pseudoephedrine, due to its favorable balance of efficacy and safety; typically, the water-soluble hydrochloride, sulfate or other salts are used to formulate products. Pseudoephedrine sulfate is chemically [S-(R*,R*)]-a-[1(methylamino)ethyl] benzenemethanol sulfate with an empirical formula of (CloHlsN~) 2'HZSO9 and a molecular weight of 428.54. The extraction of this compound from Ma Huang, and chemical synthesis of the compound, are well known in the art. For purposes of the present invention, pseudoephedrine salts may be administered in any of several dosage forms, including, without limitation, tablets, capsules, syrups or by injection;
as with most drugs, oral administration in the form of a tablet or capsule will be preferred for patient convenience.
_g_ Typically, pseudoephedrine sulfate or hydrochloride will be administered to adults in daily doses of 3.20 to 360 milligrams, and to children in daily doses of 60 to 180 milligrams, for the alleviation of congestion from allergic rhinitis.
However, the systemic half life of pseudoephedrine is considerably shorter than that of loratadine. In immediate release formulations, individual doses of 60 milligrams are usually administered to an adult patient four times in each 24-hour period. However, a number of extended release solid formulations are known in the art, for example to make 120 milligrams of the drug effective over a 12-hour period, and 240 milligrams effective for a full 24 hours.
It is not essential that the loratadine and decongestant be dosed together. For example, loratadine can be administered once daily, while the decongestant drug is administered more frequently to maintain a therapeutic systemic drug level. Even when the drugs are dosed together, it is not necessary that they are present in the same formulation or dosage form.
Formulations which combine doses of antihistaminic drugs and decongestant drugs are well known in the art.
For loratadine, these include a formulation containing 5 milligrams of loratadine and 60 milligrams of pseudoephedrine sulfate for immediate release from a tablet coating, together with 60 milligrams of pseudoephedrine which is released at a controlled rate from an erodible tablet matrix, for providing effectiveness over a 12-hour period; a useful product is commercially available in the United States from Schering Corporation of Kenilworth, New Jersey under the brand CLARITIN-D~ 12 HOUR. Another formulation incorporates 10 milligrams of loratadine for immediate release from a tablet coating together with 240 milligrams of pseudoephedrine which is released at a controlled rate from an erodible tablet matrix, for providing effectiveness over a 24-hour period; this technique is described in United States Patent 5,314,697 to Kwan et al. and a useful product is available in the United States from Schering Corporation under the brand CLARITIN-D~ 24 HOUR. Such combination formulations will be preferred by most patients, for convenience.
The invention will be further explained with reference to the following example, which is not intended to limit the scope of the appended claims in any manner.
EXAMPLE
A clinical trial was conducted, in which 193 adult patients suffering from both asthma and rhinitis were randomized to receive either the above-described CLARITIN-D~ - 12 HOUR product or a placebo twice daily for six weeks, during the fall allergy season. All of the patients had been using, and continued to use during the study, the bronchodilator drug albuterol from a pressurized aerosol metered dose inhaler as prescribed by physicians to control asthma symptoms.
No other rhinitis or asthma medications were permitted to be used by the patients during the study.
Patients were evaluated prior to commencement of the study by, inter alia, FEV and PEF rate measurements to generate baseline data, and the evaluations were repeated weekly during the study.
Patients receiving the combination of drugs were found to experience a marked reduction of both rhinitis and asthma symptoms, as compared to the patients receiving only placebo.
Fig. 1 shows results from morning measurements of PEF rates for patients receiving loratadine and pseudoephedrine sulfate (solid line) and placebo (broken line). The ordinate is the mean change of PEF
rate from baseline values, expressed in liters per minute. There was a very clear, statistically significant improvement during the study due to the drug combination administration.
Fig. 2 is a similar representation of results from an evening measurement of PEF rates for the patients, the groups being identified as above. The similar clear, statistically significant improvement during the study is a result of the drug combination administration.
Fig. 3 is a representation of further study results, as generated by measurements of FEV in the first second ("FEV1"). The ordinate shows mean change from baseline FEV, values, expressed in liters. Data from patients receiving loratadine and pseudoephedrine sulfate are identified by the solid bar, while data from patients receiving only placebo are represented by the open bar. The very clear, statistically significant improvement in pulmonary function during the study is due to the drug combination administration.
The magnitude of improvements in pulmonary function shown herein will be important for the well-being of an asthmatic patient, regardless of whether or not the patient suffers from rhinitis.
The invention encompasses a method for improving pulmonary function of a patient suffering from asthma, comprising administering to the patient the customary rhinitis treatment-effective amounts of loratadine and a decongestant.
A preferred decongestant is pseudoephedrine, and a presently preferred daily treatment for obtaining the desired results of the invention includes 10 milligrams of loratadine and one of: 240 milligrams of pseudoephedrine, administered in a suitable extended release formulation for 24-hour effectiveness; or two daily doses of 5 milligrams of loratadine and 120 milligrams of pseudoephedrine, administered in an extended release formulation for 12-hour effectiveness;
or in up to four divided doses of immediate release formulations during 24 hours, totalling 10 milligrams of loratadine and 240 milligrams of pseudoephedrine.
Particularly with the immediate release formulations, the individual drugs can be administered separately or in a combination dosage form.
BRIEF DESCRIPTIONS OF THE DRAWINGS
Fig. 1 is a graphical representation of morning PEF data obtained in the clinical test of the example.
Fig. 2 is a graphical representation of evening PEF data obtained in the clinical test of the example.
Fig. 3 is a graphical representation of FEV data obtained in the clinical test of the example.
_7-DETAILED DESCRIPTION OF THE INVENTION
A reference herein to "customary rhinitis-effective treatment amounts" of a drug is intended to indicate those doses which are approved by any relevant regulatory agencies, such as the United States Food and Drug Administration, for use of the drug to treat symptoms of allergic rhinitis. References herein to "improving pulmonary function" are meant to include a facilitation of gas exchange processes in the lungs, particularly as shown clinically by improvements in measured FEV and/or PEF values for a patient; such improvements will usually be accompanied by a reduction in the patient's perception of shortness of breath.
Loratadine, chemically ethyl-4-(8-chloro-5,6-dihydro-11H-benzo [5, 6] cyclohepta [1, 2-b) pyridin-11-ylidene)-1-piperidinecarboxylate with an empirical formula CZZHzsC1N2O2 and a molecular weight of 382.89, is a very widely used nonsedating antihistamine drug with a superb safety profile. The active drug and its preparation are described in United States Patent 4,282,233 to Vilani. The drug may also conveniently be prepared according to the process described in United States Patent 4,731,447 to Schumacher et al. For purposes of the present invention, loratadine may be administered in any of several dosage forms, including, without limitation, tablets, capsules, syrups or by injection; as with most drugs, oral administration in the form of a tablet or capsule will be preferred for patient convenience.
An effective antihistaminic dose of loratadine ranges from about 5 to about 40 milligrams daily. Due to the systemic half-lives of loratadine and its active metabolites, the daily dose may be given once each 24 hours or divided into 2, 3, or 4 preferably equal portions for administration to match the frequency of decongestant drug dosing. A typical daily dose of _g_ loratadine for relief of the symptoms of allergic rhinitis is 10 milligrams. Schering Corporation of Kenilworth, New Jersey markets a 10 milligram loratadine tablet under the brand CLARITIN~.
Useful decongestant drugs include topical decongestants and systemic decongestants. Topical decongestants are typically administered in the form of drops or aerosols such as nasal sprays, and contain such drugs as oxymetazoline, phenylephrine, naphazoline, xylometazoline, ephedrine, epinephrine, methylhexaneamine, tetrahydrozoline and xylometazoline.
Topical decongestants are not preferred for long-term therapy, due to the eventual appearance of rhinitis medicamentosa which can usually be treated only by discontinuing administration of the drug.
Suitable systemic decongestant drug compounds for the practice of the invention include the sympathomimetic amines phenylpropanolamine, ephedrine, pseudoephedrine and phenylephrine, a reference herein to the drug specifically including pharmaceutically acceptable salts thereof, where necessary. The most widely used of these is pseudoephedrine, due to its favorable balance of efficacy and safety; typically, the water-soluble hydrochloride, sulfate or other salts are used to formulate products. Pseudoephedrine sulfate is chemically [S-(R*,R*)]-a-[1(methylamino)ethyl] benzenemethanol sulfate with an empirical formula of (CloHlsN~) 2'HZSO9 and a molecular weight of 428.54. The extraction of this compound from Ma Huang, and chemical synthesis of the compound, are well known in the art. For purposes of the present invention, pseudoephedrine salts may be administered in any of several dosage forms, including, without limitation, tablets, capsules, syrups or by injection;
as with most drugs, oral administration in the form of a tablet or capsule will be preferred for patient convenience.
_g_ Typically, pseudoephedrine sulfate or hydrochloride will be administered to adults in daily doses of 3.20 to 360 milligrams, and to children in daily doses of 60 to 180 milligrams, for the alleviation of congestion from allergic rhinitis.
However, the systemic half life of pseudoephedrine is considerably shorter than that of loratadine. In immediate release formulations, individual doses of 60 milligrams are usually administered to an adult patient four times in each 24-hour period. However, a number of extended release solid formulations are known in the art, for example to make 120 milligrams of the drug effective over a 12-hour period, and 240 milligrams effective for a full 24 hours.
It is not essential that the loratadine and decongestant be dosed together. For example, loratadine can be administered once daily, while the decongestant drug is administered more frequently to maintain a therapeutic systemic drug level. Even when the drugs are dosed together, it is not necessary that they are present in the same formulation or dosage form.
Formulations which combine doses of antihistaminic drugs and decongestant drugs are well known in the art.
For loratadine, these include a formulation containing 5 milligrams of loratadine and 60 milligrams of pseudoephedrine sulfate for immediate release from a tablet coating, together with 60 milligrams of pseudoephedrine which is released at a controlled rate from an erodible tablet matrix, for providing effectiveness over a 12-hour period; a useful product is commercially available in the United States from Schering Corporation of Kenilworth, New Jersey under the brand CLARITIN-D~ 12 HOUR. Another formulation incorporates 10 milligrams of loratadine for immediate release from a tablet coating together with 240 milligrams of pseudoephedrine which is released at a controlled rate from an erodible tablet matrix, for providing effectiveness over a 24-hour period; this technique is described in United States Patent 5,314,697 to Kwan et al. and a useful product is available in the United States from Schering Corporation under the brand CLARITIN-D~ 24 HOUR. Such combination formulations will be preferred by most patients, for convenience.
The invention will be further explained with reference to the following example, which is not intended to limit the scope of the appended claims in any manner.
EXAMPLE
A clinical trial was conducted, in which 193 adult patients suffering from both asthma and rhinitis were randomized to receive either the above-described CLARITIN-D~ - 12 HOUR product or a placebo twice daily for six weeks, during the fall allergy season. All of the patients had been using, and continued to use during the study, the bronchodilator drug albuterol from a pressurized aerosol metered dose inhaler as prescribed by physicians to control asthma symptoms.
No other rhinitis or asthma medications were permitted to be used by the patients during the study.
Patients were evaluated prior to commencement of the study by, inter alia, FEV and PEF rate measurements to generate baseline data, and the evaluations were repeated weekly during the study.
Patients receiving the combination of drugs were found to experience a marked reduction of both rhinitis and asthma symptoms, as compared to the patients receiving only placebo.
Fig. 1 shows results from morning measurements of PEF rates for patients receiving loratadine and pseudoephedrine sulfate (solid line) and placebo (broken line). The ordinate is the mean change of PEF
rate from baseline values, expressed in liters per minute. There was a very clear, statistically significant improvement during the study due to the drug combination administration.
Fig. 2 is a similar representation of results from an evening measurement of PEF rates for the patients, the groups being identified as above. The similar clear, statistically significant improvement during the study is a result of the drug combination administration.
Fig. 3 is a representation of further study results, as generated by measurements of FEV in the first second ("FEV1"). The ordinate shows mean change from baseline FEV, values, expressed in liters. Data from patients receiving loratadine and pseudoephedrine sulfate are identified by the solid bar, while data from patients receiving only placebo are represented by the open bar. The very clear, statistically significant improvement in pulmonary function during the study is due to the drug combination administration.
The magnitude of improvements in pulmonary function shown herein will be important for the well-being of an asthmatic patient, regardless of whether or not the patient suffers from rhinitis.
Claims (18)
1. Use of loratadine and a decongestant for the manufacture of medicaments for improving pulmonary function of a patient suffering from asthma, wherein the medicaments comprise a customary rhinitis treatment-effective amount of loratadine and a decongestant.
2. The use of claim 1, wherein the decongestant is selected from the group consisting of phenylpropanolamine, ephedrine, phenylephrine, pseudoephedrine or a combination of any two or more thereof.
3. The use of claim 1, wherein the decongestant comprises pseudoephedrine.
4. The use of claim 3, wherein pseudoephedrine is provided in an amount for administration of about 60 to about 360 milligrams per day.
5. The use of claim 3, wherein pseudoephedrine is provided in an amount for administration of about 120 to about 240 milligrams per day.
6. The use of claim 1, 2, 3, 4 or 5, wherein loratadine is provided in an amount for administration of about 5 to about 40 milligrams per day.
7. The use of claim 1, 2, 3, 4 or 5, wherein loratadine is provided in an amount for administration of about 10 milligrams per day.
8. The use of claim 1, 2, 3, 4 or 5, wherein the medicaments are adapted to provide about 10 milligrams of loratadine daily and about 120 to about 240 milligrams of pseudoephedrine daily.
9. The use of claim 1, 2, 3, 4, 5, 6, 7 or 8, wherein the loratadine and the decongestant are in separate medicament compositions.
10. The use of claim 1, 2, 3, 4, 5, 6, 7 or 8, wherein the loratadine and the decongestant are in a single composition.
11. The use of claim 1, 2, 3, 4, 5, 6, 7 or 8, wherein the loratadine and the decongestant are in a single solid composition in which the loratadine and a portion of the decongestant are present in a coating, and the remaining decongestant is present in an erodible matrix.
12. The use of claim 1, 2, 3, 4, 5, 6, 7 or 8, wherein the loratadine and the decongestant are in a single solid composition in which the loratadine is present in a coating and the decongestant is present in an erodible matrix.
13. A pharmaceutical combination for improving pulmonary function of a patient suffering from asthma comprising a customary rhinitis treatment-effective amount of loratadine, and a decongestant.
14. A combination of claim 13, wherein said decongestant comprises pseudoephedrine.
15. A pharmaceutical formulation for improving pulmonary function of a patient suffering from asthma comprising a customary rhinitis treatment-effective amount of loratadine, and a decongestant, in a single composition.
16. A formulation of claim 15, wherein the loratadine and the decongestant are in a single solid composition in which the loratadine and a portion of the decongestant are present in a coating, and the remaining decongestant is present in an erodible matrix.
17. A formulation of claim 15, wherein the loratadine and the decongestant are in a single solid composition in which the loratadine is present in a coating and the decongestant is present in an erodible matrix.
18. A formulation of claim 15, 16 or 17, wherein said decongestant is pseudoephedrine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73966996A | 1996-10-31 | 1996-10-31 | |
| US08/739,669 | 1996-10-31 | ||
| PCT/US1997/019158 WO1998018470A1 (en) | 1996-10-31 | 1997-10-29 | Composition, for the treatment of asthma, containing loratadine and a decongestant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2268546A1 true CA2268546A1 (en) | 1998-05-07 |
Family
ID=24973307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002268546A Abandoned CA2268546A1 (en) | 1996-10-31 | 1997-10-29 | Composition, for the treatment of asthma, containing loratadine and a decongestant |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0941091A1 (en) |
| JP (1) | JP2000505104A (en) |
| KR (1) | KR20000052922A (en) |
| CN (1) | CN1235545A (en) |
| AR (1) | AR008908A1 (en) |
| AU (1) | AU731756B2 (en) |
| BR (1) | BR9712705A (en) |
| CA (1) | CA2268546A1 (en) |
| CO (1) | CO4910128A1 (en) |
| CZ (1) | CZ150999A3 (en) |
| HU (1) | HUP9904075A3 (en) |
| ID (1) | ID23431A (en) |
| IL (1) | IL129662A0 (en) |
| NO (1) | NO992062L (en) |
| NZ (1) | NZ335078A (en) |
| PE (1) | PE11399A1 (en) |
| PL (1) | PL333056A1 (en) |
| SK (1) | SK54599A3 (en) |
| TR (1) | TR199901003T2 (en) |
| WO (1) | WO1998018470A1 (en) |
| ZA (1) | ZA979731B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1032392A4 (en) * | 1997-10-29 | 2001-05-09 | J Med Pharmaceuticals Inc | Antihistamine/decongestant regimens for treating rhinitis |
| US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| IT1303671B1 (en) * | 1998-07-28 | 2001-02-23 | Nicox Sa | SALTS OF NITRIC ACID WITH ACTIVE DRUGS IN THE TREATMENT OF DISEASES OF THE RESPIRATORY SYSTEM |
| AU6018899A (en) * | 1998-09-10 | 2000-04-03 | Schering Corporation | Antihistamines for treating non-infective sinusitis or otitis media |
| US6521254B2 (en) | 1998-12-07 | 2003-02-18 | J-Med Pharmaceuticals, Inc. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| KR100505899B1 (en) * | 1999-02-23 | 2005-08-01 | 주식회사유한양행 | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine |
| CN1161112C (en) * | 1999-02-23 | 2004-08-11 | 株式会社柳韩洋行 | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine |
| WO2000057880A1 (en) * | 1999-03-29 | 2000-10-05 | Schering Corporation | Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine |
| WO2001045668A2 (en) * | 1999-12-20 | 2001-06-28 | Schering Corporation | Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| SK287105B6 (en) * | 1999-12-20 | 2009-12-07 | Schering Corporation | Bilayer sustained release oral dosage composition |
| EP1276502A1 (en) * | 2000-04-14 | 2003-01-22 | J-Med Pharmaceuticals, Inc. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| AU2001264806A1 (en) * | 2000-05-25 | 2001-12-03 | Schering Corporation | Stable liquid and solid formulations |
| WO2003000264A1 (en) * | 2001-06-20 | 2003-01-03 | Schering Corporation | Antihistamines for the treatment of nasal congestion and nasal obstruction |
| CA2612179C (en) | 2005-06-17 | 2016-08-02 | Aft Pharmaceuticals Limited | A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion |
| JP5175278B2 (en) * | 2006-06-01 | 2013-04-03 | エムエスディー コンシューマー ケア， インコーポレイテッド | Phenylephrine pharmaceutical formulations and compositions for colonic absorption |
| NZ573174A (en) * | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| KR101540191B1 (en) * | 2014-02-24 | 2015-07-28 | 성균관대학교산학협력단 | Composition comprising Loratadine for anti-inflammation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1110397A (en) * | 1964-10-02 | 1968-04-18 | Mead Johnson & Co | Ephedrine composition |
| US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5314697A (en) * | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| US5595997A (en) * | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
-
1997
- 1997-10-29 CO CO97063641A patent/CO4910128A1/en unknown
- 1997-10-29 EP EP97912874A patent/EP0941091A1/en not_active Withdrawn
- 1997-10-29 AU AU49953/97A patent/AU731756B2/en not_active Ceased
- 1997-10-29 CZ CZ991509A patent/CZ150999A3/en unknown
- 1997-10-29 WO PCT/US1997/019158 patent/WO1998018470A1/en not_active Application Discontinuation
- 1997-10-29 BR BR9712705-1A patent/BR9712705A/en not_active Application Discontinuation
- 1997-10-29 KR KR1019990703790A patent/KR20000052922A/en not_active Application Discontinuation
- 1997-10-29 NZ NZ335078A patent/NZ335078A/en unknown
- 1997-10-29 SK SK545-99A patent/SK54599A3/en unknown
- 1997-10-29 CN CN97199404A patent/CN1235545A/en active Pending
- 1997-10-29 IL IL12966297A patent/IL129662A0/en unknown
- 1997-10-29 PL PL97333056A patent/PL333056A1/en unknown
- 1997-10-29 PE PE1997000968A patent/PE11399A1/en not_active Application Discontinuation
- 1997-10-29 ZA ZA9709731A patent/ZA979731B/en unknown
- 1997-10-29 TR TR1999/01003T patent/TR199901003T2/en unknown
- 1997-10-29 HU HU9904075A patent/HUP9904075A3/en unknown
- 1997-10-29 JP JP10520579A patent/JP2000505104A/en active Pending
- 1997-10-29 AR ARP970105033A patent/AR008908A1/en not_active Application Discontinuation
- 1997-10-29 ID IDW990280D patent/ID23431A/en unknown
- 1997-10-29 CA CA002268546A patent/CA2268546A1/en not_active Abandoned
-
1999
- 1999-04-29 NO NO992062A patent/NO992062L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ID23431A (en) | 2000-04-20 |
| CN1235545A (en) | 1999-11-17 |
| WO1998018470A1 (en) | 1998-05-07 |
| HUP9904075A2 (en) | 2000-05-28 |
| IL129662A0 (en) | 2000-02-29 |
| KR20000052922A (en) | 2000-08-25 |
| PL333056A1 (en) | 1999-11-08 |
| ZA979731B (en) | 1998-04-29 |
| NZ335078A (en) | 2000-10-27 |
| JP2000505104A (en) | 2000-04-25 |
| EP0941091A1 (en) | 1999-09-15 |
| CO4910128A1 (en) | 2000-04-24 |
| TR199901003T2 (en) | 1999-07-21 |
| AU4995397A (en) | 1998-05-22 |
| AR008908A1 (en) | 2000-02-23 |
| NO992062D0 (en) | 1999-04-29 |
| PE11399A1 (en) | 1999-02-09 |
| HUP9904075A3 (en) | 2002-02-28 |
| NO992062L (en) | 1999-04-29 |
| AU731756B2 (en) | 2001-04-05 |
| BR9712705A (en) | 1999-10-26 |
| CZ150999A3 (en) | 1999-10-13 |
| SK54599A3 (en) | 2000-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU731756B2 (en) | Composition, for the treatment of asthma, containing loratadine and a decongestant | |
| Aaronson | Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma | |
| KR101841442B1 (en) | Methods of providing weight loss therapy in patients with major depression | |
| ZA200500152B (en) | Use of reboxetine for the treatment of hot flashes | |
| Bousquet et al. | A 12‐week, placebo‐controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis | |
| Corren et al. | Comparison of once‐daily mometasone furoate versus once‐daily budesonide in patients with moderate persistent asthma | |
| Nightingale et al. | Comparison of the effects of salmeterol and formoterol in patients with severe asthma | |
| Kilfeather et al. | Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft MistTM Inhaler in patients with COPD | |
| Georgitis et al. | Ipratropium bromide nasal spray in non‐allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life | |
| von Berg et al. | Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma | |
| US5376672A (en) | Method for treating tension type headaches or headaches associated with drugs or their withdrawal | |
| Baroody et al. | Ipratropium bromide (Atrovent nasal spray) reduces the nasal response to methacholine | |
| Mattson et al. | Preventive effect of ketotifen, a new antiallergic agent, on histamine‐induced bronchoconstriction in asthmatics | |
| Ishizuka et al. | Gender and age risks for hoarseness and dysphonia with use of a dry powder fluticasone propionate inhaler in asthma. | |
| Kaiser et al. | Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis | |
| Corren et al. | Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions | |
| MXPA99003936A (en) | Composition, for the treatment of asthma, containing loratadine and a decongestant | |
| EP2121021A2 (en) | Methods for treating nasal congestion in hypertensive or diabetic patients | |
| EP1569650B1 (en) | Use of levocetirizine for the treatment of persistent allergic rhinitis | |
| Frew et al. | Effects of 4-week treatment with low-dose budesonide (100 μg BID) from a novel inhaler AirmaxTM and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma | |
| WO2008085392A1 (en) | Methods for treating nasal congestion in hepatically impaired patients | |
| McDonald et al. | Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstruction | |
| Tan et al. | Double‐blind comparison of the protective effect of sodium cromoglycate and ketotifen on exercise‐induced asthma in adults | |
| White et al. | Comparative effects of fexofenadine and montelukast on allergen-induced wheal and flare | |
| Chuchalin et al. | Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler™) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer®) in children with persistent asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |